Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates Lexicon (LXRX) delivered earnings and revenue surprises of 18.18% and 215.37%, respectively, for the quarter ended December 2024. Do the…
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain Conference call and webcast at 8:00 a.m. ET on Monday, March 3, 2025 Conference call and webcast at 8:00 a.m.…
Lexicon Pharmaceuticals to Participate in December Investor Conferences THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company…
Lexicon Appoints Ivan H. Cheung to Board of Directors THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan…
Lexicon Pharmaceuticals: Exklusive Partnerschaft mit Viatris bietet gemäß der Experten gigantisches Potenzial! Lexicon Pharmaceuticals Inc. (LXRX) ist ein Biotech mit Fokus auf Behandlungsmethoden von schwerwiegenden chronischen Krankheiten. Das Unternehmen nutzt dabei die…
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three…
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024 THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation…
Lexicon Pharmaceuticals secures $250 million in private financing By Investing.com Lexicon Pharmaceuticals secures $250 million in private financing…
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced it…